from USPATOLD
NEWS 29 JAN 02 STN pricing information for 2008 now available
NEWS 30 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32 JAN 28 MARPAT searching enhanced
NEWS 33 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 34 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:24:37 ON 01 FEB 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.68	1.68

FILE 'REGISTRY' ENTERED AT 20:29:23 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6
DICTIONARY FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10594996.str





```
chain nodes :
13  14  15  16  17  18  19  22  23  26  27  28  29  30  31
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12
chain bonds :
5-13  7-30  8-14  9-29  10-28  11-15  12-31  13-14  15-16  15-26  15-27
16-17  16-22  16-23  17-18  17-19
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12
exact/norm bonds :
7-30  8-14  9-29  10-28  12-31  15-26  15-27  16-22  16-23  17-18  17-19
exact bonds :
5-13  11-15  13-14  15-16  16-17
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12
isolated ring systems :
containing 1 : 7 :


G1:O,N

G2:H,X,Ak

G3:H,O,X,Ak

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom
10:Atom  11:Atom  12:Atom  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS
 18:CLASS  19:CLASS  22:CLASS  23:CLASS  26:CLASS  27:CLASS  28:CLASS
29:CLASS  30:CLASS  31:CLASS



L1       STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 20:29:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     4505 TO ITERATE

 44.4% PROCESSED     2000 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        86075 TO    94125
PROJECTED ANSWERS:           12338 TO    15502

L2           50 SEA SSS SAM L1

=> s l1 ful
```

FULL SEARCH INITIATED 20:30:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 90745 TO ITERATE

100.0% PROCESSED 90745 ITERATIONS 14329 ANSWERS
SEARCH TIME: 00.00.02

L3 14329 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\105949961.str





chain nodes :

13 14 15 16 17 18 19 22 23 26 27 28 29 30 31 33 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
2-33 5-13 7-30 8-14 9-29 10-28 11-15 12-31 13-14 15-16 15-26
15-27 16-17 16-22 16-23 17-18 17-19 33-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
7-30 8-14 9-29 10-28 12-31 15-26 15-27 16-22 16-23 17-18 17-19
33-34
exact bonds :
2-33 5-13 11-15 13-14 15-16 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:O,N

G2:H,X,Ak

G3:H,O,X,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 22:CLASS 23:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 33:CLASS 34:Atom

L4 STRUCTURE UPLOADED

=> s l4
SAMPLE SEARCH INITIATED 20:33:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4505 TO ITERATE

44.4% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 86075 TO 94125
PROJECTED ANSWERS: 3 TO 290

L5 3 SEA SSS SAM L4

=> s l4 ful

FULL SEARCH INITIATED 20:33:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 90745 TO ITERATE

100.0% PROCESSED 90745 ITERATIONS 132 ANSWERS
SEARCH TIME: 00.00.02

L6 132 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	360.40	362.08

FILE 'CAPLUS' ENTERED AT 20:35:16 ON 01 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Feb 2008 VOL 148 ISS 6
FILE LAST UPDATED: 31 Jan 2008 (20080131/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6
L7 5 L6

=>
Uploading C:\Program Files\Stnexp\Queries\105949962.str





chain nodes :
13 14 15 16 17 18 19 22 23 26 27 28 29 30 31 33 34 37
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
5-13 7-30 8-14 9-29 10-28 11-15 12-31 13-14 15-16 15-26 15-27
16-17 16-22 16-23 17-18 17-19 33-34 33-37
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :

7-30 8-14 9-29 10-28 12-31 15-26 15-27 16-22 16-23 17-18 17-19
33-34
exact bonds :
5-13 11-15 13-14 15-16 16-17 33-37
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:O,N

G2:H,X,Ak

G3:H,O,X,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 22:CLASS 23:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 33:CLASS 34:Atom 37:CLASS 38:Atom

L8 STRUCTURE UPLOADED

=> s l8
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 20:38:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4521 TO ITERATE

44.2% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 86388 TO 94452
PROJECTED ANSWERS: 3 TO 291

L9 3 SEA SSS SAM L8

L10 1 L9

=>
Uploading C:\Program Files\Stnexp\Queries\105949963.str





chain nodes :
12 13 14 15 16 17 18 21 22 25 26 27 28 29 30 32 33 36
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 37
chain bonds :
4-12 6-29 7-13 8-28 9-27 10-14 11-30 12-13 14-15 14-25 14-26
15-16 15-21 15-22 16-17 16-18 32-33 32-36

ring bonds :
1-2 1-5 2-3 3-37 4-5 4-37 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
6-29 7-13 8-28 9-27 11-30 14-25 14-26 15-21 15-22 16-17 16-18
32-33
exact bonds :
4-12 10-14 12-13 14-15 15-16 32-36
normalized bonds :
1-2 1-5 2-3 3-37 4-5 4-37 6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :

G1:O,N

G2:H,X,Ak

G3:H,O,X,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS
17:CLASS 18:CLASS 21:CLASS 22:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 32:CLASS 33:Atom 36:CLASS 37:Atom 38:Atom

L11 STRUCTURE UPLOADED

=> s l11
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 20:40:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4521 TO ITERATE

44.2% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 86388 TO 94452
PROJECTED ANSWERS: 0 TO 0

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content

```
L12             0 SEA SSS SAM L11


L13           0 L12

=> d his

     (FILE 'HOME' ENTERED AT 20:24:37 ON 01 FEB 2008)

     FILE 'REGISTRY' ENTERED AT 20:29:23 ON 01 FEB 2008
L1                STRUCTURE UPLOADED
L2             50 S L1
L3          14329 S L1 FUL
L4                STRUCTURE UPLOADED
L5              3 S L4
L6            132 S L4 FUL

     FILE 'CAPLUS' ENTERED AT 20:35:16 ON 01 FEB 2008
L7              5 S L6
L8                STRUCTURE UPLOADED
                  S L8

     FILE 'REGISTRY' ENTERED AT 20:38:10 ON 01 FEB 2008
L9              3 S L8

     FILE 'CAPLUS' ENTERED AT 20:38:11 ON 01 FEB 2008
L10             1 S L9
L11               STRUCTURE UPLOADED
                  S L11

     FILE 'REGISTRY' ENTERED AT 20:40:32 ON 01 FEB 2008
L12             0 S L11

     FILE 'CAPLUS' ENTERED AT 20:40:32 ON 01 FEB 2008
L13             0 S L12

=> dup rem l10 l7
PROCESSING COMPLETED FOR L10
PROCESSING COMPLETED FOR L7
L14             5 DUP REM L10 L7 (1 DUPLICATE REMOVED)

=> d l14 ibib abs hitstr hitind 1-5

L14  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN  DUPLICATE 1
ACCESSION NUMBER:         2005:1103743  CAPLUS
DOCUMENT NUMBER:          143:387061
TITLE:                    Preparation of alkoxyphenylpropanoic acid
derivatives
                          as GPR40 receptor function regulators
INVENTOR(S):              Yasuma, Tsuneo; Kitamura, Shuji; Sakai, Nozomu
PATENT ASSIGNEE(S):       Takeda Pharmaceutical Company Limited, Japan
```

SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095338	A1	20051013	WO 2005-JP6522	20050328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1731505	A1	20061213	EP 2005-727536	20050328
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2007213364	A1	20070913	US 2006-594996	20060929
PRIORITY APPLN. INFO.:			JP 2004-101149 A	20040330
			WO 2005-JP6522 W	20050328

OTHER SOURCE(S): MARPAT 143:387061
GI



I



II

AB Title compds. I [Het = (un)substituted heterocycle; n = 0, 1; R1, R2 = H, alkyl, halo; R3 = (un)substituted hydroxy, (un)substituted amino; R4 = H, (un)substituted hydrocarbon, (un)substituted hydroxy, etc.; R5, R6 = H, alkyl, halo; R7, R8 = H, alkyl, halo, etc.] were prepared For example, 1,1'-(azodicarbonyl)dipiperidine mediated alkylation of 3-(4-hydroxyphenyl)propanoic acid Me ester with [3-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl]methanol, e.g., prepared from 4-bromo-1,3,5-trimethyl-1H-pyrazole in 2 steps, followed by hydrolysis using NaOH afforded compound II [R = 1,3,5-trimethyl-1H-pyrazol-4-yl]. Compound II [R = 2,4,5-trimethyl-3-thienyl] has function regulating effect on GPR40 (G protein-coupled receptor 40) receptor with the EC50 value of <10 nM. Compds. I are claimed useful for the treatment of diabetes. Formulations are given.

IT 866586-88-1P 866586-99-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkoxyphenylpropanoic acid derivs. as GPR40 receptor function regulators for treatment of diabetes)

RN 866586-88-1 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[(2-phenyl-4-morpholinyl)methyl]phenyl]methox

y]- (CA INDEX NAME)



RN 866586-99-4 CAPLUS
CN Benzenepropanoic acid,
4-[[4-[(4-phenyl-1-piperidinyl)methyl]phenyl]methox
y]- (CA INDEX NAME)



IC ICM C07D207-08
ICS C07D207-06; C07D207-12; C07D207-16; C07D207-24; C07D207-325; C07D209-08; C07D209-10; C07D209-22; C07D211-08; C07D211-18; C07D211-46; C07D211-60; C07D213-36; C07D215-06; C07D217-04; C07D223-16; C07D231-12; C07D233-60; C07D235-18
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT 866586-15-4P 866586-17-6P 866586-21-2P 866586-23-4P 866586-26-7P
866586-29-0P 866586-31-4P 866586-33-6P 866586-34-7P 866586-35-8P
866586-37-0P 866586-39-2P 866586-40-5P 866586-41-6P 866586-42-7P
866586-43-8P 866586-44-9P 866586-45-0P 866586-46-1P 866586-47-2P
866586-48-3P 866586-49-4P 866586-50-7P 866586-51-8P 866586-52-9P
866586-53-0P 866586-54-1P 866586-55-2P 866586-56-3P 866586-58-5P
866586-59-6P 866586-60-9P 866586-61-0P 866586-62-1P 866586-63-2P
866586-64-3P 866586-65-4P 866586-66-5P 866586-67-6P 866586-68-7P
866586-69-8P 866586-70-1P 866586-71-2P 866586-72-3P 866586-73-4P
866586-74-5P 866586-75-6P 866586-76-7P 866586-77-8P 866586-78-9P
866586-80-3P 866586-82-5P 866586-83-6P 866586-84-7P 866586-85-8P

866586-86-9P 866586-87-0P 866586-88-1P 866586-89-2P
866586-90-5P 866586-91-6P 866586-92-7P 866586-93-8P
866586-94-9P
866586-95-0P 866586-96-1P 866586-97-2P 866586-98-3P
866586-99-4P 866587-00-0P 866587-02-2P 866587-04-4P
866587-06-6P 866587-08-8P 866587-10-2P 866587-12-4P
866587-14-6P
866587-16-8P 866587-18-0P 866587-20-4P 866587-22-6P
866587-24-8P
866587-26-0P 866587-28-2P 866587-30-6P 866587-32-8P
866587-34-0P
866587-36-2P 866587-38-4P 866587-40-8P 866587-42-0P
866587-44-2P
866587-46-4P 866587-47-5P 866587-48-6P 866587-50-0P
866587-51-1P
866587-52-2P 866587-54-4P 866587-57-7P 866587-60-2P
866587-63-5P
866587-65-7P 866587-67-9P 866587-69-1P 866587-71-5P
866587-73-7P
866587-75-9P 866587-77-1P 866587-79-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkoxyphenylpropanoic acid derivs. as GPR40 receptor function regulators for treatment of diabetes)
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1026833 CAPLUS
DOCUMENT NUMBER: 143:326090
TITLE: Preparation of arylmethoxyphenyl-alkylcarboxylic acids
and related derivatives for use in treating metabolic
disorders
INVENTOR(S): Akerman, Michelle; Houze, Jonathan; Lin, Daniel C. H.;
Liu, Jiwen; Luo, Jian; Medina, Julio C.; Qiu, Wei; Reagan, Jeffrey D.; Sharma, Rajiv; Shuttleworth, Stephen J.; Sun, Ying; Zhang, Jian; Zhu, Liusheng
PATENT ASSIGNEE(S): Amgen Inc., USA; et al.
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005086661	A2	20050922	WO 2005-US5815	20050224
WO 2005086661	A3	20060504		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005220728	A2	20050922	AU 2005-220728	20050224
AU 2005220728	A1	20050922		
CA 2558585	A1	20050922	CA 2005-2558585	20050224
EP 1737809	A2	20070103	EP 2005-723623	20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1946666	A	20070411	CN 2005-80012709	20050224
BR 2005008098	A	20070717	BR 2005-8098	20050224
JP 2007525516	T	20070906	JP 2007-500959	20050224
US 2006004012	A1	20060105	US 2005-67377	20050225
MX 2006PA09793	A	20061030	MX 2006-PA9793	20060828
US 2007142384	A1	20070621	US 2006-591214	20060828
KR 2007004769	A	20070109	KR 2006-719713	20060922
IN 2006DN05525	A	20070817	IN 2006-DN5525	20060922
NO 2006004362	A	20061122	NO 2006-4362	20060926
PRIORITY APPLN. INFO.:			US 2004-548741P	P 20040227
			US 2004-601579P	P 20040812
			WO 2005-US5815	W 20050224

OTHER SOURCE(S): MARPAT 143:326090

GI



II

AB Title compds. Q-L1-P-L2-M-X-L3-A [Q = H, (hetero)aryl, alkyl, etc.; L1 = bond, alkylene, heteroalkylene, O, etc.; P = (hetero)aromatic, cycloalkylene, etc.; L2 = bond, alkylene, heteroalkylene, etc.; M = (hetero)aromatic, cycloalkylene, arylalkylene, etc.; X = divalent alkyl, (un)substituted-N; O, SO0-2; L3 = bond, alkylene, heteroalkylene, etc.; A = COOH, tetrazolyl, SO3H, PO3H2, etc.; I] are prepared For instance, (S)-3-[4-((4'-trifluoromethyl-1,1'-biphenyl-3-yl)methoxy)phenyl]hexan-4-ynoic acid (II) is prepared in 5 steps from (S)-3-(4-hydroxyphenyl)hexan-4-ynoic acid Me ester (preparation given), 4-(trifluoromethyl)phenylboronic acid and 3-bromobenzoic acid. II has an EC50 < 0.1 μM for human G protein-coupled receptor GPR40. I are useful for the treatment of type II diabetes.

IT 865231-78-3P 865231-79-4P 865231-80-7P
865231-81-8P 865233-00-7P 865233-01-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivs.
as GPCR40 ligands for use in treating metabolic disorders)

RN 865231-78-3 CAPLUS
CN Benzenepropanoic acid, β-1-propynyl-4-[[4-(2-pyridinyl)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 865231-79-4 CAPLUS
CN Benzenepropanoic acid, β-1-propynyl-4-[[4-(3-pyridinyl)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 865231-80-7 CAPLUS
CN Benzenepropanoic acid, β-1-propynyl-4-[[4-(4-pyridinyl)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 865231-81-8 CAPLUS
CN Benzenepropanoic acid, β-1-propynyl-4-[[4-(1H-pyrrol-1-yl)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 865233-00-7 CAPLUS

CN Benzenepropanoic acid, 4-[[4-(1H-benzimidazol-2-yl)phenyl]methoxy]-β-1-propynyl- (9CI) (CA INDEX NAME)



RN 865233-01-8 CAPLUS
CN Benzenepropanoic acid, β-1-propynyl-4-[[4-(1H-1,2,4-triazol-1-yl)phenyl]methoxy]- (9CI) (CA INDEX NAME)



IC ICM A61K
CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
IT 86271-60-5P 113085-35-1P 113085-36-2P 119998-52-6P 865231-45-4P
865231-46-5P 865231-47-6P 865231-48-7P 865231-49-8P
865231-50-1P
865231-51-2P 865231-52-3P 865231-53-4P 865231-54-5P
865231-55-6P
865231-56-7P 865231-57-8P 865231-58-9P 865231-59-0P
865231-60-3P
865231-61-4P 865231-62-5P 865231-63-6P 865231-64-7P
865231-65-8P
865231-66-9P 865231-67-0P 865231-68-1P 865231-69-2P
865231-70-5P
865231-71-6P 865231-72-7P 865231-73-8P 865231-74-9P
865231-75-0P
865231-76-1P 865231-77-2P 865231-78-3P 865231-79-4P
865231-80-7P 865231-81-8P 865231-82-9P 865231-84-1P
865231-85-2P 865231-86-3P 865231-87-4P 865231-88-5P
865231-89-6P
865231-91-0P 865231-92-1P 865231-93-2P 865231-94-3P
865231-95-4P
865231-96-5P 865231-97-6P 865231-98-7P 865231-99-8P
865232-00-4P
865232-01-5P 865232-02-6P 865232-03-7P 865232-04-8P
865232-05-9P
865232-06-0P 865232-07-1P 865232-08-2P 865232-09-3P
865232-10-6P

865232-11-7P 865232-12-8P 865232-13-9P 865232-14-0P
865232-15-1P
865232-16-2P 865232-17-3P 865232-18-4P 865232-19-5P
865232-20-8P
865232-21-9P 865232-22-0P 865232-23-1P 865232-24-2P
865232-25-3P
865232-26-4P 865232-27-5P 865232-28-6P 865232-29-7P
865232-30-0P
865232-31-1P 865232-32-2P 865232-33-3P 865232-34-4P
865232-35-5P
865232-36-6P 865232-37-7P 865232-38-8P 865232-39-9P
865232-40-2P
865232-41-3P 865232-42-4P 865232-43-5P 865232-44-6P
865232-45-7P
865232-46-8P 865232-47-9P 865232-48-0P 865232-49-1P
865232-50-4P
865232-51-5P 865232-52-6P 865232-53-7P 865232-54-8P
865232-55-9P
865232-56-0P 865232-57-1P 865232-58-2P 865232-59-3P
865232-60-6P
865232-61-7P 865232-62-8P 865232-63-9P 865232-64-0P
865232-65-1P
865232-67-3P 865232-68-4P 865232-69-5P 865232-70-8P
865232-71-9P
865232-72-0P 865232-73-1P 865232-74-2P 865232-75-3P
865232-76-4P
865232-77-5P 865232-78-6P 865232-79-7P 865232-80-0P
865232-81-1P
865232-82-2P 865232-83-3P 865232-84-4P 865232-85-5P
865232-86-6P
865232-87-7P 865232-88-8P 865232-89-9P 865232-90-2P
865232-91-3P
865232-92-4P 865232-93-5P 865232-94-6P 865232-95-7P
865232-96-8P
865232-97-9P 865232-98-0P 865232-99-1P 865233-00-7P
865233-01-8P 865233-02-9P 865233-03-0P 865233-04-1P
865233-05-2P 865233-06-3P 865233-07-4P 865233-08-5P
865233-09-6P
865233-10-9P 865233-11-0P 865233-12-1P 865233-13-2P
865233-14-3P
865233-15-4P 865233-16-5P 865233-17-6P 865233-18-7P
865233-19-8P
865233-20-1P 865233-21-2P 865233-22-3P 865233-23-4P
865233-24-5P
865233-25-6P 865233-26-7P 865233-27-8P 865233-28-9P
865233-29-0P
865233-30-3P 865233-31-4P 865233-32-5P 865234-04-4P
865234-05-5P
865303-22-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylmethoxyphenyl-alkylcarboxylic acids and related derivs.
as GPCR40 ligands for use in treating metabolic disorders)

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:154382 CAPLUS
DOCUMENT NUMBER: 138:187795
TITLE: Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
INVENTOR(S): Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1009 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003016254	A1	20030227	WO 2002-JP8120		20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2457468	A1	20030227	CA 2002-2457468		20020808
AU 2002323916	A1	20030303	AU 2002-323916		20020808
EP 1431267	A1	20040623	EP 2002-755874		20020808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002011810	A	20040824	BR 2002-11810		20020808
CN 1551866	A	20041201	CN 2002-817376		20020808
HU 2004001963	A2	20050128	HU 2004-1963		20020808
NZ 531153	A	20051028	NZ 2002-531153		20020808
NZ 541950	A	20070223	NZ 2002-541950		20020808
RU 2315746	C2	20080127	RU 2004-106623		20020808
ZA 2004000973	A	20050104	ZA 2004-973		20040205
NO 2004000564	A	20040510	NO 2004-564		20040206
MX 2004PA01253	A	20040603	MX 2004-PA1253		20040209
US 2006258728	A1	20061116	US 2004-486220		20040909
PRIORITY APPLN. INFO.:			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808

OTHER SOURCE(S): MARPAT 138:187795
GI



I

AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepared These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisoindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide

, (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reproduction disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers associated therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, reduction of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis.

Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester
was mesylated by methanesulfonyl chloride in the presence of Et3N in THF
at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the
binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2,
EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038
μM, resp. A tablet formulation containing (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT 499156-52-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic
acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499156-52-4 CAPLUS

CN Benzenepropanoic acid, 2-[[[1-(3,5-dimethylphenyl)-3-methylbutyl]amino]carbonyl]-4-[[4-(2-pyridinyl)phenyl]methoxy]- (CA INDEX NAME)



IC ICM C07C057-40
ICS C07C057-44; C07C069-736; C07C229-34; C07C233-47; C07C233-55; C07C233-65; C07C233-81; C07C233-87; C07C235-38; C07C235-42; C07C235-46; C07C235-48; C07C235-54; C07C235-56; C07C237-30; C07C239-18; C07C255-37; C07C255-55; C07C255-57

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 25, 27, 63

IT 499153-99-0P 499154-00-6P 499154-01-7P 499154-02-8P 499154-03-9P
499154-04-0P 499154-05-1P 499154-06-2P 499154-07-3P 499154-08-4P
499154-09-5P 499154-10-8P 499154-11-9P 499154-12-0P 499154-13-1P

499154-14-2P 499154-15-3P 499154-16-4P 499154-17-5P 499154-18-6P
499154-20-0P 499154-21-1P 499154-22-2P 499154-23-3P 499154-24-4P
499154-25-5P 499154-27-7P 499154-28-8P 499154-30-2P 499154-31-3P
499154-32-4P 499154-33-5P 499154-35-7P 499154-36-8P 499154-38-0P
499154-40-4P 499154-43-7P 499154-44-8P 499154-46-0P 499154-48-2P
499154-49-3P 499154-51-7P 499154-53-9P 499154-55-1P 499154-57-3P
499154-59-5P 499154-60-8P 499154-62-0P 499154-64-2P 499154-65-3P
499154-67-5P 499154-69-7P 499154-71-1P 499154-72-2P 499154-74-4P
499154-76-6P 499154-78-8P 499154-80-2P 499154-82-4P 499154-84-6P
499154-86-8P 499154-88-0P 499154-90-4P 499154-92-6P 499154-94-8P
499154-95-9P 499154-97-1P 499154-98-2P 499154-99-3P 499155-00-9P
499155-01-0P 499155-02-1P 499155-03-2P 499155-04-3P 499155-05-4P
499155-06-5P 499155-07-6P 499155-09-8P 499155-11-2P 499155-12-3P
499155-13-4P 499155-14-5P 499155-15-6P 499155-16-7P 499155-17-8P
499155-18-9P 499155-19-0P 499155-20-3P 499155-21-4P 499155-22-5P
499155-23-6P 499155-24-7P 499155-25-8P 499155-26-9P 499155-27-0P
499155-28-1P 499155-29-2P 499155-30-5P 499155-31-6P 499155-32-7P
499155-33-8P 499155-34-9P 499155-35-0P 499155-36-1P 499155-37-2P
499155-38-3P 499155-39-4P 499155-40-7P 499155-41-8P 499155-42-9P
499155-43-0P 499155-44-1P 499155-45-2P 499155-46-3P 499155-47-4P
499155-48-5P 499155-49-6P 499155-50-9P 499155-51-0P 499155-52-1P
499155-53-2P 499155-54-3P 499155-57-6P 499155-60-1P 499155-63-4P
499155-65-6P 499155-66-7P 499155-68-9P 499155-70-3P 499155-72-5P
499155-74-7P 499155-75-8P 499155-77-0P 499155-79-2P 499155-81-6P
499155-83-8P 499155-86-1P 499155-88-3P 499155-89-4P 499155-90-7P
499155-92-9P 499155-94-1P 499155-95-2P 499155-97-4P 499155-98-5P

499155-99-6P 499156-00-2P 499156-01-3P 499156-02-4P
499156-03-5P
499156-04-6P 499156-05-7P 499156-06-8P 499156-07-9P
499156-08-0P
499156-09-1P 499156-10-4P 499156-11-5P 499156-12-6P
499156-13-7P
499156-14-8P 499156-15-9P 499156-16-0P 499156-17-1P
499156-18-2P
499156-19-3P 499156-20-6P 499156-21-7P 499156-22-8P
499156-23-9P
499156-24-0P 499156-25-1P 499156-26-2P 499156-27-3P
499156-28-4P
499156-29-5P 499156-30-8P 499156-31-9P 499156-32-0P
499156-33-1P
499156-34-2P 499156-35-3P 499156-36-4P 499156-37-5P
499156-38-6P
499156-39-7P 499156-40-0P 499156-41-1P 499156-42-2P
499156-43-3P
499156-44-4P 499156-45-5P 499156-46-6P 499156-47-7P
499156-48-8P
499156-49-9P 499156-50-2P 499156-51-3P 499156-52-4P
499156-53-5P 499156-54-6P 499156-55-7P 499156-56-8P
499156-57-9P
499156-58-0P 499156-59-1P 499156-60-4P 499156-61-5P
499156-62-6P
499156-63-7P 499156-64-8P 499156-65-9P 499156-66-0P
499156-67-1P
499156-68-2P 499156-69-3P 499156-70-6P 499156-71-7P
499156-72-8P
499156-73-9P 499156-74-0P 499156-75-1P 499156-76-2P
499156-77-3P
499156-78-4P 499156-79-5P 499156-80-8P 499156-81-9P
499156-82-0P
499156-83-1P 499156-84-2P 499156-85-3P 499156-86-4P
499156-87-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic
acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:435186 CAPLUS
DOCUMENT NUMBER: 135:55020
TITLE: Substituted phthalocyanines and their precursors
INVENTOR(S): Cook, Michael John; Heeney, Martin James

PATENT ASSIGNEE(S): Gentian AS, Norway
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042368	A1	20010614	WO 2000-GB4708	20001208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2394891	A1	20010614	CA 2000-2394891	20001208
EP 1238016	A1	20020911	EP 2000-985506	20001208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003516421	T	20030513	JP 2001-543656	20001208
EE 200200298	A	20030815	EE 2002-298	20001208
HU 2003001099	A2	20030828	HU 2003-1099	20001208
HU 2003001099	A3	20031128		
NO 2002002663	A	20020808	NO 2002-2663	20020605
PRIORITY APPLN. INFO.:			GB 1999-29064 A	19991208
			GB 2000-12348 A	20000522
			GB 2000-25817 A	20001020
			WO 2000-GB4708 W	20001208

OTHER SOURCE(S): MARPAT 135:55020
AB Process is claimed for the preparation of metal phthalocyanines and their precursors including phthalonitrile sulfonate esters, substituted phthalonitriles and substituted phthalocyanines, phthalonitrile halides.
For example 3,6-didecylphthalonitrile was prepared from 3,6-bis(trifluoromethanesulfonyloxy)phthalonitrile and decylzinc iodide and reacted with 4,5-dibromo-3,6-dibutoxyphthalonitrile, prepared from bromination of 2,3-dicyanohydroquinone, in presence of Ni(OAc)2.4H2O to give [1,4-dibutoxy-2,3-dibromo-8,11,15,18,22,25-hexadecylphthalocyaninato]nickel. The metal phthalocyanine derivs. have applications as photosensitizers for use in photodynamic therapy.
IT 344454-03-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 344454-03-1 CAPLUS
CN Zinc, [butyl
O-[[4-[1,4-dibutoxy-8,11,15,18,22,25-hexakis(decyl)-29H,31H-
phthalocyanin-2-yl-κN29,κN30,κN31,κN32]phenyl]meth
yl]tyrosinato(2-)]-, (SP-4-2)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



IC ICM C09B047-067
ICS C09B047-04; C07D487-22; A61K041-00; C07D487-22; C07D259-00; C07D209-00; C07D209-00; C07D209-00; C07D209-00
CC 78-7 (Inorganic Chemicals and Reactions)
Section cross-reference(s): 8, 28, 63, 74
IT 344453-48-1P 344453-52-7P 344453-53-8P 344453-58-3P 344453-60-7P
344453-63-0P 344453-64-1P 344453-65-2P 344453-82-3P 344453-83-4P
344453-84-5P 344453-85-6P 344453-86-7P 344453-87-8P 344453-91-4P
344453-92-5P 344453-95-8P 344453-96-9P 344453-97-0P 344453-98-1P
344454-03-1P 344570-54-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:91520 CAPLUS
DOCUMENT NUMBER: 120:91520
TITLE: Preparation of optically active biphenylcarboxylic and
esters as liquid crystals and liquid crystal compositions containing said esters
INVENTOR(S): Nohira, Hiroyuki; Aoki, Yoshio; Nakamura, Shinichi
PATENT ASSIGNEE(S): Canon Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 49 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05221927	A	19930831	JP 1992-26828	19920213

PRIORITY APPLN. INFO.: JP 1992-26828 19920213

OTHER SOURCE(S): MARPAT 120:91520
GI



AB The title compds. I (R1, R2 = alkyl; X1 = single bond, O, CO2, etc.; X2 =
CO2, CH2O; A1, A2 = Q1, Q2, etc.; n = 0, 1; C* indicates optical active C
atom) were prepared Reaction of acid chloride II with optically active

phenol derivative III in the presence of triethylenediamine gave title compound
IV with [α]D = -18° (chloroform). IV showed a phase transition temperature of 75.5° between the SA and Iso phases.

IT 152191-92-9
RL: PRP (Properties)
(liquid crystal composition)

RN 152191-92-9 CAPLUS

CN Benzenepropanoic acid, 4-[[2-fluoro-4-(5-methoxy-2-pyrimidinyl)phenyl]methoxy]-β-(trifluoromethyl)-, undecyl ester, mixt. with 5-decyl-2-[4-(octyloxy)phenyl]pyrimidine, 5-decyl-2-[4-[[2-(trifluoromethyl)octyl]oxy]phenyl]pyrimidine, 5-dodecyl-2-[4-[[2-(trifluoromethyl)octyl]oxy]phenyl]pyrimidine, 2-[4-(hexyloxy)phenyl]-5-octylpyrimidine, 2-[4-(nonyloxy)phenyl]-5-octylpyrimidine, trans-4-(5-undecyl-2-pyrimidinyl)phenyl 4-butylcyclohexanecarboxylate, trans-4-(5-undecyl-2-pyrimidinyl)phenyl 4-pentylcyclohexanecarboxylate and trans-4-(5-undecyl-2-pyrimidinyl)phenyl 4-propylcyclohexanecarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 152191-91-8
CMF C33 H40 F4 N2 O4



CM 2

CRN 152191-81-6
CMF C31 H47 F3 N2 O



CM 3

CRN 152191-80-5
CMF C29 H43 F3 N2 O



CM 4

CRN 121639-89-2
CMF C32 H48 N2 O2

Relative stereochemistry.



CM 5

CRN 121639-88-1
CMF C31 H46 N2 O2

Relative stereochemistry.



CM 6

CRN 121083-94-1
CMF C33 H50 N2 O2

Relative stereochemistry.



CM 7

CRN 57202-62-7
CMF C28 H44 N2 O



CM 8

CRN 57202-51-4
CMF C27 H42 N2 O



CM 9

CRN 57202-48-9
CMF C24 H36 N2 O



IC ICM C07C069-773
ICS C07C069-736; C07C069-75; C07C069-753; C07C069-757; C07C069-92; C07C069-94; C09K019-20; C09K019-30; C09K019-34; C09K019-42
CC 75-11 (Crystallography and Liquid Crystals)
Section cross-reference(s): 74
IT 152191-82-7 152191-84-9 152191-86-1 152191-88-3 152191-90-7 152191-92-9
RL: PRP (Properties)
(liquid crystal composition)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.01	397.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

STN INTERNATIONAL LOGOFF AT 20:41:59 ON 01 FEB 2008